Please upgrade your browser.
SGN-75, undergoing a phase I trial for metastatic renal cell carcinoma...
igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma (RCC).
Reliable data on familial risks are important for clinical counseling and cancer genetics.
New cancer drugs are technically impressive. But must they cost so much?
Information about renal cell carcinoma may be found in these abstracts that were presented recently at the world's largest oncology meeting, held in Chicago. The Kidney Cancer Association sponsored the presentation of this information.
We conducted a direct drug-to-drug comparison of the two regulatory agencies approvals of new oncology drugs.
Spring 2011 edition is online.
tthe first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma (RCC).
As early as 1932, physicians noticed an apparent association between type 2 diabetes and increased cancer risk. In recent years, the epidemiological evidence of such an association has mounted steadilyespecially with the emergence of large databases, which have allowed us to document the link.
|Powered by NeonCRM|